A cent short of coverage — book value down 17% in a quarter. A monthly payer at $0.24 a share, $2.88 annualized, held unchanged through the third quarter — and third-quarter distributable earnings of $0.71 a share covered all but a cent of the quarter's $0.72 of dividends. That is essentially covered, but the quarter behind it is brutal: book value fell 17% in three months to $14.55, down from $18.63 at December 31, 2025, for a negative 12.9% economic return and a $327 million GAAP net loss on Agency MBS marks as spreads widened late in the quarter. Implied leverage ran above 8× equity on a $21.3 billion, overwhelmingly Agency MBS portfolio. The dividend is still paid out of spread earnings, not out of capital returned, which is what keeps this a warning rather than a trap — but a one-cent coverage margin on a book that just lost 17% is a warning with very little room.
Key risk: Rates and spreads — Agency MBS marks and funding costs drive book value here, and at above 8× leverage a spread-widening quarter like the third does to book value what the dividend cannot repair. If distributable earnings slip further below $0.72 a quarter, the $0.24 monthly rate has no cushion left.
Changes if: Distributable earnings fall further below the $0.72 quarterly dividend, book value falls for a second straight quarter, or leverage rises further. Any of those turns a one-cent coverage gap into a cut question.
- !Earnings coverage check: Third-quarter distributable earnings of $0.71 a share fell a cent short of the $0.72 dividend — covered in substance, but with no cushion at all if spread income slips.
- ✗Book-value check: Book value fell 17% in the third quarter alone to $14.55, and from $18.63 at December 31, 2025 — more than a fifth of book gone in nine months while the dividend was held flat.
- !Leverage check: Implied leverage above 8× equity is what turns a bad Agency MBS quarter into a 17% book-value loss — the structure amplifies every spread move, in both directions.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.